Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line
1991
Reversal of Adriamycin Resistance by Lonidamine in Breast Cancer Cells
publication
Evidence: moderate
Author Information
Author(s): G. Citro, C. Cucco, A. Verdina, G. Zupi
Primary Institution: Regina Elena Institute for Cancer Research
Hypothesis
Can Lonidamine reverse Adriamycin resistance in human breast cancer cells?
Conclusion
The combination of Lonidamine and Adriamycin significantly enhances the cytotoxic effect on Adriamycin-resistant breast cancer cells.
Supporting Evidence
- The combination of Lonidamine and Adriamycin reduced the IC50 values significantly for both cell lines.
- Lonidamine allowed Adriamycin to reach similar intracellular levels in resistant cells as in sensitive cells.
- The study demonstrated that Lonidamine can restore sensitivity to Adriamycin in resistant breast cancer cells.
Takeaway
Lonidamine helps make cancer cells that are resistant to a drug called Adriamycin more sensitive to it again.
Methodology
The study involved treating two types of human breast cancer cell lines with Adriamycin alone and in combination with Lonidamine, measuring cell viability and intracellular drug content.
Statistical Information
P-Value
0.0002 to 0.04
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website